ClinicalTrials.gg

Program

ECC0509

A development code.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Liver Diseases, led by Eccogene.

Furthest: phase 2, since Dec 15, 20253 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eccogene32 open or runningphase 2since Dec 15, 2025Jul 22, 2021Mar 2027phase 1 · NCT07873229

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 22, 2021First study: phase 1 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT05012423 · 89 enrolled · Australia
  2. Dec 15, 2025Phase 2 study in Liver DiseasesPhase 2 reachedNCT07288138 · 160 planned · United States
  3. Sep 16, 2026Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT07873229 · 40 planned · Australia

Ahead

  1. Mar 2027Primary completion: phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT07873229
  2. Sep 15, 2027Primary completion: phase 2 study in Liver DiseasesNCT07288138

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07873229Non-alcoholic Fatty Liver Disease · Australia1Not yet recruitingMar 202740
NCT07288138Liver Diseases · United States2RecruitingSep 15, 2027160
NCT05012423Non-alcoholic Fatty Liver Disease · Australia1CompletedJul 22, 202389

How it is read

Names in the registry

  • “ECC0509”, 4 entries

Codes read as this program: ECC0509.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.